ofloxacin has been researched along with Musculoskeletal Diseases in 3 studies
Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.
Musculoskeletal Diseases: Diseases of the muscles and their associated ligaments and other connective tissue and of the bones and cartilage viewed collectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Levofloxacin was well tolerated during and for 1 month after therapy as evidenced by similar incidence and character of adverse events compared with nonfluoroquinolone antibiotics." | 2.73 | Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. ( Arguedas, A; Bagchi, P; Balis, DA; Blumer, JL; Bradley, JS; Duffy, CM; Gerbino, PG; Kauffman, RE; Noel, GJ, 2007) |
| "We studied the pharmacokinetic and pharmacodynamic parameters of levofloxacin and rifampicin in bone and joint infections." | 1.38 | Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections. ( Bensalem, M; Bland, S; Bru, JP; Gaillat, J; Garraffo, R; Guillaume, M; Janssen, C, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Huruba, M | 1 |
| Farcas, A | 1 |
| Leucuta, DC | 1 |
| Bucsa, C | 1 |
| Sipos, M | 1 |
| Mogosan, C | 1 |
| Guillaume, M | 1 |
| Garraffo, R | 1 |
| Bensalem, M | 1 |
| Janssen, C | 1 |
| Bland, S | 1 |
| Gaillat, J | 1 |
| Bru, JP | 1 |
| Noel, GJ | 1 |
| Bradley, JS | 1 |
| Kauffman, RE | 1 |
| Duffy, CM | 1 |
| Gerbino, PG | 1 |
| Arguedas, A | 1 |
| Bagchi, P | 1 |
| Balis, DA | 1 |
| Blumer, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Long-Term, Active-Surveillance Study of Musculoskeletal Disorders That Occur After Initiating a Course of Levofloxacin (RWJ-25213-097) or Non-Fluoroquinolone Therapy for Acute Infectious Diseases in Children Who Were Enrolled in Phase 3 Cli[NCT00210639] | 2,233 participants (Actual) | Observational | 2002-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The criteria used to assess Musculoskeletal Adverse Event is based on system organ class Musculoskeletal and connective tissue disorders of MedDRA 13.0." (NCT00210639)
Timeframe: Musculoskeletal Disorder (MSD) Follow-Up phase (ie, up to 5 years after their first dose of antimicrobial therapy, yearly visits for 4 additional years)
| Intervention | Participants (Number) |
|---|---|
| Levofloxacin | 3 |
| Comparator | 3 |
1 trial available for ofloxacin and Musculoskeletal Diseases
| Article | Year |
|---|---|
Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Child; Child, Preschool; Female; Humans; In | 2007 |
2 other studies available for ofloxacin and Musculoskeletal Diseases
| Article | Year |
|---|---|
A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Adverse Drug Reaction Reporting Systems; Arthralgia; Cip | 2021 |
Pharmacokinetic and dynamic study of levofloxacin and rifampicin in bone and joint infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Area Under Curve; Arthritis, Infectious; Body Mass Index; Discit | 2012 |